Clinical Trial Update: A Phase I Trial of Intranasal Peptide T: Safety, Toxicity, and Pharmacokinetics in Human Immunodeficiency Virus-1 (HIV-1) Infected Patients. [Phase 1]

View source ↗

Summary

This Phase I trial evaluated the safety, toxicity, and pharmacokinetics of intranasal Peptide T in HIV-1 infected patients.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• HIV Infection

Drugs mentioned

• Peptide T (peptide T)

Snippet

Sponsor: National Institute of Mental Health (NIMH) | Conditions: HIV Infections | Phase 1 | Status: COMPLETED